Skip to search formSkip to main contentSkip to account menu

tesetaxel

A semi-synthetic, orally bioavailable taxane derivative with potential antineoplastic and antiangiogenic properties. Tesetaxel binds to and… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

DJ927
Microtubule ProcessNCIt Antineoplastic Agent Terminology

Broader (1)

Taxoids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally…
TPS1107 Background: Chemotherapy treatments with robust efficacy that preserve quality of life are needed. Tesetaxel (T) is a… 
2018
2018
Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.
1042Background: Chemotherapy treatments that offer improved quality of life are needed. Tesetaxel (T) is a novel, oral taxane… 
2012
2012
Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer.
1016 Background: Tesetaxel, unlike standard taxanes (docetaxel, paclitaxel), is not a substrate for Pgp, a major cause of taxane… 
2012
2012
Phase I development of a weekly dosing schedule for the oral taxane tesetaxel.
2555 Background: Tesetaxel (TST) has anticancer activity in patients (pts) with metastatic breast cancer (MBC) and gastric cancer… 
2011
2011
Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer.
TPS123 Background: Taxanes such as docetaxel and paclitaxel are among the most active agents in metastatic breast cancer (MBC… 
2011
2011
P5-19-11: Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer.
Background Parenteral taxanes (docetaxel, paclitaxel) are among the most active agents in treating metastatic breast cancer (MBC… 
2010
2010
Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent.
e13075 Background: Currently approved taxanes are given intravenously and associated with marked hypersensitivity and cumulative… 
2010
2010
An intersubject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors.
TPS159 Background: Tesetaxel is an orally active tubulin-binding inhibitor that has completed multiple phase II trials. In… 
2009
2009
Pharmacokinetics (PK) and safety of tesetaxel, an orally administered taxane, in a study examining a range of doses including the active phase II dose.
e13535 Background: Tesetaxel is an orally active taxane with potent cytotoxic activity against various cancer cell lines in vitro… 
Review
2006
Review
2006
Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative.
Daiichi Sankyo Co Ltd (formerly Daiichi Seiyaku Co Ltd) was developing the oral semisynthetic taxane derivative tesetaxel for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)